AGM
HRTX icon

Alpine Global Management’s Heron Therapeutics HRTX Stock Holding History

Alpine Global Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,164
Closed -$22.9K – 220
2023
Q1 		$22.9K Sell
15,164
-18,127
-54% -$45.4K 0.01% 92
2022
Q4 		$83K Buy
+33,291
New +$107K 0.03% 348

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Alpine Global Management's HRTX Position: Q2 2023 in Review

Alpine Global Management sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 15,164 shares — an estimated $22.9K sold.

Alpine Global Management first reported a position in HRTX in Q4 2022 and held it in 2 quarters. The position peaked at $83K in Q4 2022. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Alpine Global Management reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Alpine Global Management sold 15,164 Heron Therapeutics shares in Q2 2023, an estimated $22.9K.
  • Alpine Global Management first reported a position in Heron Therapeutics in Q4 2022 and held it in 2 quarters.
  • Alpine Global Management's Heron Therapeutics position peaked at $83K in Q4 2022.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Alpine Global Management's 13F filing for Q2 2023, filed 14 Aug 2023.